Skip to content
10-Q

Quarterly Report

Akero Therapeutics, Inc.

0000950170-24-123689

← back to feed
Filed
Nov 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 31, 2024 69.8M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $316.07M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $234.21M
Current Liabilities Q3 2024 · Sep 30, 2024 $43.29M
Current Liabilities Q3 2024 · Dec 31, 2023 $19.13M
Total Liabilities Q3 2024 · Sep 30, 2024 $79.22M
Total Liabilities Q3 2024 · Dec 31, 2023 $44.97M
Current Assets Q3 2024 · Sep 30, 2024 $746.89M
Current Assets Q3 2024 · Dec 31, 2023 $559.96M
Total Assets Q3 2024 · Sep 30, 2024 $817.55M
Total Assets Q3 2024 · Dec 31, 2023 $580.27M
Shares Diluted Q3 2024 · Sep 30, 2023 55.61M sh
Shares Diluted Q3 2024 · Sep 30, 2023 51.51M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$96.74M
Stockholders Equity Q3 2024 · Sep 30, 2023 $583.14M
Stockholders Equity Q3 2024 · Jun 30, 2023 $616.44M
Stockholders Equity Q3 2024 · Mar 31, 2023 $306.35M
Stockholders Equity Q3 2024 · Dec 31, 2022 $326.56M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.71
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.87
Eps Basic Q3 2024 · Sep 30, 2023 −$0.71
Eps Basic Q3 2024 · Sep 30, 2023 −$1.87
Sga Expense Q3 2024 · Sep 30, 2023 $7.98M
Sga Expense Q3 2024 · Sep 30, 2023 $22.59M
Rd Expense Q3 2024 · Sep 30, 2023 $38.63M
Rd Expense Q3 2024 · Sep 30, 2023 $88.41M
Net Income Q3 2024 · Sep 30, 2023 −$39.66M
Net Income Q3 2024 · Sep 30, 2023 −$96.57M
Net Income Q3 2024 · Jun 30, 2023 −$31.08M
Net Income Q3 2024 · Mar 31, 2023 −$25.83M
Net Income Q3 2024 · Dec 31, 2022 −$112.03M
Operating Income Q3 2024 · Sep 30, 2023 −$46.62M
Operating Income Q3 2024 · Sep 30, 2023 −$111M